iShares Core High Dividend ETF vs Oscar Health Inc — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while Oscar Health Inc trades at $33.83 (market cap $10.22B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and Oscar Health Inc is trading nearer its 52-week high, iShares Core High Dividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Oscar Health Inc for 15 Days on average.
| HDV | OSCR | |
|---|---|---|
Market Cap | $14.68B | $10.22B |
Volume | 2,925,562 | 4,123,394 |
52-Week High | $29.93 | $33.81 |
52-Week Low | $23.64 | $10.85 |
Typical Hold Time | 117 Days | 15 Days |
Sector | — | Health |
Enterprise Value | — | $6.57B |
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% on the day, with technical indicators showing a neutral to bearish bias. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. This shift creates heightened concentration risk with 62% of assets in just three sectors, offering a 3% yield that may not adequately compensate for reduced diversification according to Seeking Alpha analysis from September 28, 2026.
The outlook remains cautious as HDV's sector concentration and modest yield face headwinds from rising interest rates. While high-dividend ETFs are outperforming the S&P 500 in 2026 according to 24/7 Wall Street, HDV's structural changes introduce execution risk. Investors should weigh the trade-off between current income and long-term diversification benefits, particularly as the Fed continues tightening monetary policy.
OSCR trades at $32.91, up 1.76% today, with a bullish technical outlook from moving averages and mixed oscillators. The stock shows strong revenue growth, with 2026 revenue projected at $15.3B, and profitability turning positive with a net income margin of 3.59%. Recent news highlights market share gains in the ACA sector and raised 2026 guidance, though Q3 2026 EPS is yet to be reported.
The outlook is positive with analyst consensus at Buy and a $34 price target, but risks include rising medical costs and execution challenges. Upside potential exists from scalable growth and margin expansion, yet volatility near resistance levels and competitive pressures warrant caution for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →